Evidence map›Paper›PMID 32117322›Full record

ArticleFrontiers in immunology2020

Md Huzzatul Mursalin, Phillip S Coburn, Erin Livingston, Frederick C Miller, Roger Astley, Ana L Flores-Mireles, Michelle C Callegan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Role of C-X-C Chemokines in Staphylococcus aureus Endophthalmitis.Investigative ophthalmology & visual science · 2023
    Article
  9. Virulence-related genotypic differences amongFrontiers in cellular and infection microbiology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. TheMicrobiology (Reading, England) · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Anemoside B4 protects againstChinese medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Md Huzzatul MursalinDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Phillip S CoburnDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Erin LivingstonDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Frederick C MillerDepartment of Cell Biology and Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Roger AstleyDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Ana L Flores-MirelesDepartment of Biological Sciences, University of Notre Dame, South Bend, IN, United States.
Michelle C CalleganDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
University of Oklahoma Health Sciences Center · USDean McGee Eye Institute · USUniversity of Notre Dame · US

Funding

P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
Pathogenic Mechanisms of Bacillus EndophthalmitisR01EY028810 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2018 to 2022
$1.8M
Vascular Permeability and Ocular InfectionsR01EY024140 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2014 to 2017
$1.6M
Nanotherapeutics for Ocular InfectionsR01EY025947 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C, ZHANG, LIANGFANG · 2015 to 2017
$1.1M
Targeting Chemokines in Intraocular InfectionR21EY028066 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2019 to 2020
$399k
NEI NIH HHS P30 EY021725NEI NIH HHS R01 EY024140NEI NIH HHS R01 EY025947NEI NIH HHS R01 EY028810NEI NIH HHS R21 EY028066
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBacillus thuringiensisBacterial AdhesionBacterial Outer Membrane ProteinsDisease Models, AnimalEndophthalmitisEpendymoglial CellsGram-Positive Bacterial InfectionsHL-60 CellsHumansImmunity, InnateMembrane GlycoproteinsMiceMice, Inbred C57BLNeutrophilsPhagocytosisBacterial Outer Membrane ProteinsMembrane Glycoproteinsoxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholinePhosphatidylcholinesS-layer proteinsTLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Bacillusendophthalmitisimmune responseinflammationocular infectionS-layerTLRs

Identifiers

PMID32117322
PMCPMC7028758
OpenAlexW3006039359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.